1. Регистр лекарственных средств России 2010–2012. URL: http://www.rlsnet.ru/.
2. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719.
3. Longo R, Torino F, Gasparini G. Targeted therapy of breast cancer. Curr Pharm Des 2007; 13: 497–517.
4. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–92.
5. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265–74.
6. Gasparini G, Gion M, Mariani L et al. Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with HER-2 positive advanced breast cancer. Breast Cancer Res Treat 2007; 101: 355–65.
7. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03–05 Study. J Clin Oncol 2009; 27: 1999–2006.
8. Bartsch R, Wenzel C, Gampenrieder SP et al. Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. Cancer Chemother Pharmacol 2008; 62: 903–10.
9. Cardoso F, Costa A, Norton L et al. 1st International consensus guidelines for advanced breast cancer. Breast 2012; 21: 242–52.
10. Gomez HL, Doval DC, Chavez MA et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008; 26: 2999–3005.
11. Guan Z-Z, Xu B-H, Arpornwirat W et al. Overall survival benefit observed with lapatinib plus paclitaxel as first line therapy in patients with HER2-overexpressed metastatic breast cancer. Cancer Res 2010; 10 (Suppl.): Abstract P3–14–24.
12. Di Leo A, Gomez HL, Aziz Z et al. Phase III double-blind randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
13. Gelmon KA, Boyle F, Kaufman B et al. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy with lapatinib or trastuzumab as first line therapy for women with HER2+ metastatic breast cancer: Interim analysis of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol 2012; 30 (Suppl.): Abstract LBA671.
14. Untch M, Loibl S, Bischoff J et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012; 13: 135–44.
15. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733–43.
16. Cameron D, Casey M, Oliva C et al. Lapatinib plus capecitabin in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010; 15: 924–34.
17. Magdelaine-Beuzelin С, Kaas Q, Wehbi V et al. Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment. Crit Rev Oncol Hematol 2007; 64: 210–25.
18. Baselga J, Cortés J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109–19.
19. Swain S et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncology 2013; 14: 461–71.
20. Baselga J, Bradbury I, and Eidtmann H. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379 (9816): 616.
21. Guarneri V, Frassoldati A, Bottini A et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clinic Oncol 2012; 30 (16): 1989–95.
22. Robidoux A, Tang G, Rastogi P et al. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. J Clin Oncol 2012; 30: Abstract LBA506.
23. Gianni L, Pienkowski T, Im Y-H et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncology 2012; 13 (1): 25–32.
24. Schneeweiss A, Chia S, Hickish T et al. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: A Randomized Phase II Study (TRYPHAENA). Cancer Res 2011; 71 (24, Suppl. 3): Abstract S5–6.
25. Beck A, Haeuw JF, Wurch T et al. The next generation of antibody drug conjugates comes from age. Discovery Med 2010; 10 (53): 329–39.
26. Krop IE, Beeram M, Modi S et al. Phase I study of trastuzumab-DM1, a HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28: 398–405.
27. Blackwell KL, Miles D, Gianni L et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane. J Clin Oncol 2012; 30 (Suppl.): Abstract LBA1.
28. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783–91.
29. Hurvitz SA, Dirix L, Kocsis J et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2013; 31 (9): 1157–63.
30. U.S. FDA. Full Prescribing Information for Kadcyla PDF (556 kB). Retrieved 2012–02–23.
31. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2 positive, hormone receptor positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27: 5529–37.
32. Johnston S, Pippen JrJ, Pivot X, Lichinitser M et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27: 5538–46.
33. Huober J, Fasching PA, Barsoumc M et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – results of the eLEcTRA trial. Breast 2011; 1: 7.
34. Giordano SH, Temin S, Kirshner JJ et al. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Published online before print: May 5, 2014. DOI: 10.1200/ JCO.2013.54.094.
35. Swain S, Kim S et al. Final overall survival analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab, and docetaxel in patients with HER2-positive metastatic breast cancer. ESMO 2014: Absract 350O_PR. 

М.Б.Стенина

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Российской академии медицинских наук, Москва

________________________________________________

M.B.Stenina